Overcoming endocrine therapy resistance by signal transduction inhibition

Oncologist

Volumn 9, Issue SUPPL. 3, 2004, Pages 20-26

  Ellis, Matthew ^a,b  

^a USA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; ErbB; Estrogen receptor; HER 2; Inhibition; Tyrosine kinase

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; FADROZOLE; FULVESTRANT; GEFITINIB; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB;

BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; META ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FARNESYLTRANSTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NITRILES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIROLIMUS; TAMOXIFEN; TRIAZOLES;

EID: 2942565669     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_3-20     Document Type: Review

References (52)

1. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
2. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-3767.
3. Dombemowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
4. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-1411.
5. Buzdar A, Jonat W, Howell A et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-2011.
6. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
7. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER 1/2 expression status. Cancer Res 2003;63:6523-6531.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
9. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-3105.
10. Ciocca DR, Fujimura FK, Tandon AK et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992;84:1279-1282.
11. Oh AS, Lorant LA, Holloway JN et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001;15:1344-1359.
12. Bolton RG, Cobleigh M, Vogel C et al. Estrogen receptor (ER) status does not predict benefit to trastuzumab (Herceptin): a review of the Herceptin clinical trials experience. Proc Am Soc Clin Oncol 2001;20:44a.
13. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
14. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-2446.
15. Liu Y, el-Ashry D, Chen D et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995;34:97-117.
16. Newby JC, Johnston SR, Smith IE et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-1651.
17. Nicholson RI, Hutcheson IR, Harper ME et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175-182.
18. Nicholson RI, Hutcheson IR, Harper ME et al. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 2002;963:104-115.
19. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001;7(suppl):4436s-4442s; discussion 4411s-4412s.
20. Witters LM, Kumar R, Chinchilli VM et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997;42:1-5.
21. Witters L, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep 2002;9:1163-1166.
22. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9:511S-515S.
23. Kurokawa H, Lenferink AE, Simpson JF et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-5894.
24. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191-195.
25. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen. Proc Am Soc Clin Oncol 2003;22:3.
26. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
27. De Laurentis M, Bianco AR, Placido S. A meta-analysis of the interaction between HER2 expression and response to endocrine treatment in advanced breast cancer. Biological Therapy of Cancer 2000;2:11-14.
28. Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:1967-1972.
29. Hu JC, Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 2001;27:335-337.
30. Love RR, Duc NB, Havighurst TC et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21:453-457.
31. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
32. Schiff R, Massarweh S, Shou J et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447S-454S.
33. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-361.
34. Girault I, Lerebours F, Amarir S et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003;9:1259-1266.
35. Wong ZW, Isaacs C, Harris L et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S106.
36. Lipton A, Ali SM, Leitzel K et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-1472.
37. Cariou S, Donovan JC, Flanagan WM et al. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000;97:9042-9046.
38. Johnston SR, Kelland LR. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr Relat Cancer 2001;8:227-235.
39. James GL, Goldstein JL, Brown MS et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 1993;260:1937-1942.
40. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999;19:1831-1840.
41. Ashar HR, James L, Gray K et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-30457.
42. Johnston SRD. Endocrine therapy combined with the farnesyl transferase inhibitor (FTI) R115777 produces enhanced tumor growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo. Breast Cancer Res Treat 2002;76:S71.
43. Doisneau-Sixou SF, Cestac P, Faye JC et al. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 2003;106:789-798.
44. Campbell RA, Bhat-Nakshatri P, Patel NM et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-9824.
45. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs 2002;3:1249-1253.
46. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-258.
47. Peralba JM, DeGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887-2892.
48. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003;4:126-137.
49. Filipits M, Pohl G, Rudas M et al. Predictive value of p27KIP1 expression in premenopausal women with early-stage hormone receptor-positive breast cancer. Proc Am Soc Clin Oncol 2003;22:3.
50. Viglietto G, Motti ML, Bruni P et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-1144.
51. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002;8:1076-1078.
52. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.